Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and MannKind Corporation

Ultragenyx vs. MannKind: A Decade of R&D Spending

__timestampMannKind CorporationUltragenyx Pharmaceutical Inc.
Wednesday, January 1, 201410024400045967000
Thursday, January 1, 201529674000114737000
Friday, January 1, 201614917000183204000
Sunday, January 1, 201714118000231644000
Monday, January 1, 20188737000293998000
Tuesday, January 1, 20196900000357355000
Wednesday, January 1, 20206248000412084000
Friday, January 1, 202112312000497153000
Saturday, January 1, 202219721000705789000
Sunday, January 1, 202331283000648449000
Loading chart...

Igniting the spark of knowledge

Innovation in Pharmaceuticals: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Ultragenyx Pharmaceutical Inc. and MannKind Corporation have demonstrated contrasting approaches to research and development (R&D) spending. From 2014 to 2023, Ultragenyx has consistently increased its R&D investment, peaking at approximately 705% of its 2014 spending by 2022. This commitment underscores their focus on pioneering treatments and therapies. In contrast, MannKind's R&D expenditure has fluctuated, with a notable decline of about 93% from 2014 to 2019, before a modest recovery in recent years. By 2023, MannKind's R&D spending was still only about 31% of its 2014 peak. This divergence highlights Ultragenyx's aggressive pursuit of innovation compared to MannKind's more conservative approach. As the pharmaceutical landscape evolves, these strategies will undoubtedly shape their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025